Keryx price target raised to $25 from $16 at Maxim Maxim raised its price target for Keryx shares to $25 on expectations the company is now positioned to launch Zerenex by itself or with a partner following its capital raise. The firm keeps a Buy rating on the stock.
Keryx survey results positive, says Oppenheimer After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.